Hence, CD95L stimulation can make both AML cells and non-tumor cells sensitive to BV6/FLIPin, with AML cells being much more sensitive to FLIPin/BV6 without CD95 stimulation than primary T cells. The gene discussed is FAS; the disease is acute myeloid leukemia.